Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 for Relapsed/Refractory CD19+ B-cell Malignancies
NCT05705570Phase 1Recruiting
- Start
- Feb 2023
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zorpocabtagene autoleucel in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Primary endpoint: Recommended Phase 2 Dose at 28 days. Started Feb 2023; status: recruiting.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05705570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705570.